Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05920616 · ClinicalTrials.gov registry record · NA

Comprehensive Imaging Exam of Convalesced COVID-19 Patients

A NA study, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
206
Enrollment target

NCT05920616: Completed NA study, sponsored by Johns Hopkins University.

NCT05920616 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 206 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05920616, a NA study, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
206 participants
Enrollment target

Study Summary

COVID-19 is a systemic inflammatory disease involving many organs including the lungs, vascular system liver and myocardium that lead to severe pathologies. Patients with severe cardiopulmonary symptoms usually require weeks to months to fully recover. Studies of clinical and subclinical impairments of COVID-19 patients are important for medical practice and public health as well as providing pathogenic insight to the viral infection and secondary immune response. Chronic damage of vital organs and systems, and the potential long-term effects is of serious concern. In this study the investigators plan to quantify and characterize chronic consequences of COVID-19 in individuals who receive similar medical care related to disease severity and duration in a single health care system. Using state-of-the-art Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) technology, we will study the pathology in major organ systems in comparison to matched controls. The results of this study may facilitate measures to prevent, detect, and manage complications from COVID-19 infections.

Primary Outcome

\- MRI to assess degree and extent of fibrosis in the liver, lungs, brain, myocardium, and vascular systems

Interventions

  • OTHER Magnetic Resonance Imaging
  • OTHER Ultra-High Resolution Computed Tomography (CT) Scan

Trial Details

FieldValue
Enrollment Target 206 participants
Start Date 2020-10-14
Est. Completion 2026-05-15
Phase NA
Johns Hopkins University

1,448 total trials

What the finished NCT05920616 record still lists

NCT05920616 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 2 interventions - of which Magnetic Resonance Imaging is the first listed.

NCT05920616 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05920616 about?

NCT05920616 is a clinical study titled "Comprehensive Imaging Exam of Convalesced COVID-19 Patients". COVID-19 is a systemic inflammatory disease involving many organs including the lungs, vascular system liver and myocardium that lead to severe pathologies. Patients with severe cardiopulmonary symptoms usually require weeks to months to fully recover. Studies of clinical and subclinical impairments...

What is the current status of trial NCT05920616?

This trial is currently completed. It is a NA study. The enrollment target is 206 participants. The study started on 2020-10-14. Estimated completion is 2026-05-15.

What interventions are being tested in trial NCT05920616?

The interventions under investigation include: Magnetic Resonance Imaging (OTHER), Ultra-High Resolution Computed Tomography (CT) Scan (OTHER).

Who is sponsoring clinical trial NCT05920616?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05920616's enrollment target sits among peer trials

206 499th of 2000 higher than 1,502 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03373968 · 206 participants · Phase 2

    Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

  • NCT03550391 · 206 participants · Phase 3

    Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

  • NCT04757116 · 206 participants · NA

    Post-Market Study to Assess iTind Safety in Comparison to UroLift

  • NCT05675865 · 206 participants · NA

    Cryoablation for Monomorphic Ventricular Tachycardia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05920616, the US trial registry maintained by the National Library of Medicine. NCT05920616 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.